Prospective Cohort With Clinic-biologic Database of Patients Treated by Immunotherapy
ConditionSolid Tumor, Adult
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCentre Oscar Lambret
About this trial
ImmuCCo-1905 is a monocentric interventional study on patients treated by immunotherapy, which consist in establishment of a prospective clinic-biologic database over 5 years, associated with a biobank. This database will allow carrying out works aiming at assessing immunotherapy in real life situation.
Eligibility criteria
Qualifiers
Age ≥ 18 years
Beginning a first immunotherapy by immune checkpoint inhibitor - anti-PD1 (Programmed cell Death protein-1), anti-PDL1 (Programmed cell Death protein-1 ligand), anti-CTLA4 (Cytotoxic T-Lymphocyte associated protein 4), as monotherapy or in combination, in the Centre Oscar Lambret (COL)
In neo-adjuvant, adjuvant, recurrence or metastatic situation
Suffering from solid tumor histologically documented
Disqualifiers
Pregnant or breastfeeding women
Patient already treated by immunotherapy by immune checkpoint inhibitor
Person under guardianship
Inability to comply with medical follow-up of the trial (geographical, social or psychic reasons)
Trial design
Treatments tested in this trial
- ImmuCCo Cohort
Treatment groups
651 Participants
are divided into 1 treatment groupSponsors and collaborators
Centre Oscar Lambret
Lead sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Collaborator
Source ClinicalTrials.gov